Background: Group 2 innate lymphoid cells (ILC2s) expand in the lungs of mice during type 2 inflammation induced by the fungal allergen Alternaria alternata. The increase in ILC2 numbers in the lung has been largely attributed to local proliferation and whether ILC2s migrate from the circulation to the lung after Alternaria exposure is unknown. Objective: We examined whether human (lung, lymph node, and blood) and mouse lung ILC2s express b 1 and b 2 integrin adhesion molecules and whether these integrins are required for trafficking of ILC2s into the lungs of mice. Methods: Human and mouse ILC2s were assessed for surface expression of b 1 and b 2 integrin adhesion molecules by using flow cytometry. The role of b 1 and b 2 integrins in ILC2 trafficking to the lungs was assessed by in vivo blocking of these integrins before airway exposure to Alternaria in mice. Results: Both human and mouse lung ILC2s express high levels of b 1 and b 2 integrin adhesion receptors. Intranasal administration of Alternaria challenge reduced ILC2 numbers in the bone marrow and concurrently increased blood and lung ILC2 numbers. In vivo blocking of b 2 integrins (CD18) significantly reduced ILC2 numbers in the lungs but did not alter ILC2 proliferation, apoptosis, and function. In contrast, in vivo blocking of b 1 integrins or a 4 integrins did not affect lung ILC2 numbers. Conclusion: ILC2 numbers increase in the mouse lung not only through local proliferation but also through trafficking from the circulation into the lung using b 2 rather than b 1 or a 4 integrins.
Because group 2 innate lymphoid cells (ILC2s) express high levels of T H 2 cytokines (IL-4, IL-5, and IL-13), studies have focused on understanding their role in the pathogenesis of human diseases, including asthma, allergic rhinitis, and atopic dermatitis. [1] [2] [3] [4] [5] Although ILC2s and T H 2 lymphocytes are both prominent sources of T H 2 cytokines, ILC2s do not express antigen receptors and are instead activated by cytokines (ie, IL-33, thymic stromal lymphopoietin, and IL-25) and lipid mediators (ie, cysteinyl leukotrienes and prostaglandin D 2 ). 6, 7 Prostaglandin D 2 induces ILC2 T H 2 cytokine production and is also a chemotactic factor for ILC2s through binding to chemoattractant receptor-homologous molecule expressed on T H 2 cells (CRTH2), which is highly expressed by ILC2s. 8 Mediators that activate ILC2s are known to be increased in different T H 2 disease states, including asthma and allergic rhinitis. The number of ILC2s is increased in the peripheral blood, bronchoalveolar lavage fluid, and sputum of allergic and/or asthmatic patients, and several studies demonstrate increased ILC2 numbers in the lungs of mice during T H 2 inflammation. [9] [10] [11] [12] [13] Although it is well accepted that T lymphocytes use adhesion molecules to traffic from the circulation to the lung after allergen inhalation, 14 studies have not yet examined whether ILC2s migrate from the circulation to the lung after allergen challenge and, if so, which adhesion receptors expressed by ILC2s can mediate this function. Several reports have demonstrated that local proliferation of ILC2s occurs in tissues, including the lungs. [15] [16] [17] However, ILC2s are bone marrow-derived cells, and mechanisms that regulate trafficking from blood to tissues could be important during inflammatory responses. 18 Mice deficient in bone marrow CRTH2-expressing ILC2s had diminished ILC2 numbers in the lungs after Nippostrongylus brasiliensis infection, 19 suggesting that a trafficking defect might be involved, but whether ILC2-expressed adhesion receptors can account for this reduction in ILC2 numbers in the lung was not examined.
We hypothesized that bone marrow-derived ILC2s migrating through the blood express adhesion molecules that firmly bind to counterreceptors expressed by lung endothelium during allergic inflammation. This firm adhesion of ILC2s to pulmonary endothelium then allows for their subsequent migration into the tissues through chemotactic mediators, such as prostaglandin D 2 .
The most common method by which leukocytes (other than ILC2s) are known to migrate from the blood into tissues, specifically the airways, is mediated by leukocyte-expressed selectins and integrins. 20 Leukocyte-expressed selectins, such as L-selectin (CD62L), mediate the first step of leukocyte tethering to endothelium in vivo, whereas leukocyte-expressed b 1 and b 2 integrins mediate leukocyte firm adhesion to endothelium. Integrins are heterodimers comprised of a and b subunits. b 1 (CD29) integrins, such as very late antigen 4 (VLA-4; a 4 /b 1 or CD49d/ CD29), are highly expressed on eosinophils, T lymphocytes, and basophils but not neutrophils. 21, 22 VLA-4 expressed by leukocytes binds to vascular cell adhesion molecule 1 (VCAM-1 [CD106]) expressed by endothelium. In addition to b 1 integrins, b 2 and b 7 integrins expressed by leukocytes also mediate firm adhesion. For example, lymphocytes use b 2 (CD18) integrins, such as lymphocyte function-associated antigen 1 (LFA-1; a L / b 2 or CD11a/CD18), to firmly adhere to intercellular adhesion molecule 1 (ICAM-1 [CD54]) expressed by endothelium. 23 Although lymphocytes also use b 7 integrins to firmly adhere to endothelium, this interaction of lymphocyte expressed b 7 integrins (ie, a 4 /b 7 ) with endothelium is more prominent in migration of lymphocytes to the gut 24 because the counterreceptor for a 4 /b 7 (ie, mucosal vascular addressin cell adhesion molecule 1 or MAdCAM-1) is most highly expressed in the gastrointestinal tract rather than the lung, which is the focus of our ILC2 studies.
Overall, studies of b integrins and leukocyte trafficking to sites of allergic inflammation have demonstrated an important role for both b 1 and b 2 integrins in eosinophil adhesion and trafficking to tissues. 25 In contrast, for neutrophils, b 2 integrins, rather than b 1 integrins, mediate predominantly neutrophil trafficking to tissue sites of inflammation. 26 Therefore we profiled expression of integrin adhesion molecules on human and mouse ILC2s to determine which adhesion receptors were highly expressed by ILC2s and used neutralizing antibodies to demonstrate that ILC2s traffic from the circulation by using b 2 but not b 1 integrins during Alternaria-induced lung inflammation.
METHODS

Human ILC2s
Human ILC2s were identified by means of flow cytometry as CD45
1 Lin 2 CRTH2 1 lymphoid cells 8, 27 in single-cell suspensions of either postmortem human lungs and lymph nodes or human peripheral blood obtained as described in the Methods section and in Table E1 in this article's Online Repository at www.jacionline.org.
Mouse ILC2s: Airway administration of Alternaria and in vivo blocking of integrins Mice were challenged intranasally with A alternata 3 times (days 0, 3, and 6) and were sacrificed 1 day after the final challenge (day 7), as previously described 10 and detailed in the Methods section in this article's Online Repository. In experiments involving in vivo blocking of integrins, mice were administered intraperitoneally an integrin-specific blocking or control antibody (b 1 , b 2 , a 4 , or a L antibody; see Table E2 in this article's Online Repository at www. jacionline.org) before each Alternaria challenge (days 0, 3, and 6), as detailed in the Methods section in this article's Online Repository.
ILC2 proliferation, apoptosis, and T H 2 cytokines
ILC2 proliferation (Ki-67 staining), apoptosis (Annexin V staining), and T H 2 cytokines (IL-5 and IL-13 staining) were quantitated by means of flow cytometry, as described in the Methods section in this article's Online Repository.
Statistical analysis
Statistical analysis was performed with Prism software (GraphPad Software, La Jolla, Calif), as described in the Methods section in this article's Online Repository. A P value of less than .05 was considered statistically significant.
RESULTS
Human ILC2s express b 1 and b 2 integrins
Human ILC2s derived from peripheral blood, lung tissue, and intrathoracic lymph nodes were analyzed for expression of adhesion molecules by using flow cytometry to determine whether human ILC2s express adhesion molecules commonly associated with migration of other leukocytes. Human ILC2s were gated as CD45 
CRTH2
1 lymphoid cells (Fig 1, A) and detected at a mean frequency of 0.15% of CD45 1 cells in the blood, 0.04% in the lungs, and 0.06% in lung lymph nodes (Fig  1, B) . Human ILC2s highly express both the integrin chains for b 2 integrins (CD18 and CD11a) and moderately express both the integrin chains for b 1 integrins (CD29 and CD49d; Fig 1, C-E, and see Figs E1 and E2 in this article's Online Repository at www.jacionline.org). Compared with human CD4 cells, human ILC2s express similar levels of b 1 and b 2 integrin adhesion molecules (Fig 1, F-H ).
Mouse ILC2s express b 1 and b 2 integrins
To study the functional importance of ILC2 expression of adhesion molecules to recruitment of ILC2s to the lung, we used a well-validated model of Alternaria allergen challenge in nonsensitized wild-type mice, which induces a rapid innate mediated increase in the number of ILC2s. 13 To validate that mouse ILC2s expressed a similar profile of adhesion molecules as human ILC2s, expression of the same adhesion molecules was assessed by using flow cytometry on ILC2s from mouse lungs. Mouse ILC2s were identified as Lin (Fig 2, A) . We have previously used this gating strategy to show that Lin 1 cells from the same naive mouse lungs were analyzed to determine relative levels of adhesion molecule expression (Fig 2, B and C, and see Fig E3 in this article's Online Repository at www.jacionline.org).
ILC2s showed slightly higher expression levels compared with CD4 cells of the b 1 integrins CD29 (mean, 99.1% compared with 79.8%) and CD49d (mean, 90.5% compared with 79.4%), as well as the b 2 integrin CD18 (mean, 88.0% compared with 49.0%). In addition, ICAM-1 was more highly expressed on ILC2s compared with CD4 cells (mean, 98.5% compared with 65.2%), whereas both populations showed equally high percentages of CD11a expression (mean, >99%; Fig 2, B) . Interestingly, the percentage of lung CD4 cells expressing L-selectin (CD62L; mean, 80.1%) was markedly higher compared with that on lung ILC2s expressing L-selectin (mean, 4.9%; P < .0001; Fig 2, B) .
These differences were further demonstrated by the comparison of change in geometric mean fluorescence intensity (DgMFI) between the ILC2 and CD4 1 Thy1.2 1 cell populations (Fig 2, C) . Thy1.2 1 cell populations had minimal expression or DgMFI for the endothelial adhesion molecule VCAM-1 (CD106). Thus, compared with human ILC2s, mouse lung ILC2s express high levels of both b 2 (CD18/ CD11a) and b 1 (CD29/CD49d) integrins, which are at slightly higher levels compared with CD4 cells.
Effect of Alternaria challenge on levels of ILC2 adhesion molecule expression
Nonsensitized naive mice challenged with the fungal allergen A alternata over 3 days experience innate type 2 inflammation and ILC2 activation. 27 Therefore we assessed lung ILC2 adhesion molecule expression after activation in vivo by Alternaria challenge (Fig 2, D and E) . Similar to human lung ILC2s, the majority of naive non-Alternaria-challenged mouse lung ILC2s expressed high levels of the b 2 integrins CD18 (mean, 97.7%) and CD11a (mean, 98.6%), as well as the b 1 integrins CD29 (mean, 98.0%) and CD49d (mean, 86.9%). ICAM-1 levels were highly expressed in mouse lung ILC2s (mean, 98.0%). In contrast, CD62L (mean, 2.5%) and VCAM-1 (mean, 8.2%) were expressed at low levels (Fig 2, B) . After Alternaria challenge, levels of lung ILC2 expression of the b 2 integrin CD18 and the b 1 integrin CD29, as well as CD62L, ICAM-1, and VCAM-1, did not change. However, there was a minimal but statistically significant increase in the percentage of ILC2s expressing the b 2 integrin CD11a and the b 1 integrin CD49d (Fig 2, D) . There was a statistically significant increase in the DgMFI value of the mouse lung ILC2 b 2 integrin subunits CD18 (DDgMFI, 4,954) and CD11a (DDgMFI, 19,114), as well as in the b 1 integrin subunit CD49d (DDgMFI, 2,723) after Alternaria challenge (Fig 2, E) . In addition, after Alternaria challenge, levels of lung ILC2 DgMFI of CD29, CD62L, ICAM-1, and VCAM-1 did not change (Fig 2, E) . Thus Alternaria challenge in mice led to modest increases in b 1 and b 2 integrin DgMFI adhesion molecule expression but did not alter the overall expression profile.
Alternaria challenge reduced ILC2 numbers in the bone marrow and increased ILC2 numbers in the blood and lungs
To determine whether ILC2s circulate from the bone marrow to the lungs after Alternaria challenge, we assessed ILC2 numbers in the bone marrow, blood, and lungs of mice challenged every 3 days with Alternaria allergen. Mice were sacrificed 24 hours after either the second challenge on day 4 or the third challenge on day 7 (Fig 3) . Mouse bone marrow and blood ILC2s were characterized as Lin (Fig 3, A) . There were little to no detectable blood ILC2s in the naive and day 4 mice. However, Alternaria challenge significantly increased blood ILC2 numbers on day 7 compared with those in naive and day 4 mice (Fig 2, B) and adhesion molecule DgMFI (Fig 2, C; n 5 3). D and E, Comparison of mouse lung ILC2 percentage expression (Fig 2, D) and DgMFI (Fig 2, E) of adhesion molecules between naive mice (open circles) and Alternaria-challenged mice (solid circles; n 5 7). Independent experiments are depicted as individual points; the mean 6 SEM is represented as a line. *P < .05, **P < .01, and ***P < .001, Student t test. (Fig 3, B) . In addition, ILC2 numbers in lung lymph nodes and spleens were found to be increased on day 7 (see Figs E4, C and D, and E5, A and B). As expected, mice sacrificed on both days 4 and 7 had increased numbers of lung ILC2s compared with naive mice (Fig 3, C) . Summary of the changes in overall CD45 1 cell levels are depicted in Fig E5, C-G. Together, these studies demonstrate that intranasal administration of Alternaria reduced ILC2 numbers in the bone marrow and concurrently increased blood and lung ILC2 numbers on day 7.
ILC2s in the lungs after Alternaria challenge originate in bone marrow in mice
To determine whether ILC2s migrate from the bone marrow to the airways, we used mice undergoing bone marrow *** 
ILC2 numbers change in the bone marrow, blood, and lungs after Alternaria (Alt) challenge in wildtype and BMT mice. A-C, Total ILC2s from bone marrow (Fig 3, A) , blood (Fig 3, B) , and whole lung (Fig 3, C) from naive (white columns; n > _ 23), 4-day Alternaria challenged (gray columns; n 5 8), and 7-day Alternaria challenged (black columns; n > _ 14) mice. CD45.1 or CD45.2 donor bone marrow was transplanted into CD45.2-irradiated recipient mice. D, Representative plots of BMT mouse blood ILC2 expression of CD45.1 and CD45.2. E, Total CD45.1 (black columns) and CD45.2 (white columns) blood cells from BMT mice. F and G, Total ILC2s from blood (Fig 3, F) and whole lung ( the lung (n > _ 4; data were log transformed for normalcy). E, Total number of sorted ILC2s adherent to ICAM-1-coated wells compared with control-coated wells with or without preincubation of ILC2s with aCD18 (2 independent experiments). F, Total ILC2s per lung of mice treated with or without Alternaria and with or without anti-CD11a antibody (n > _ 6). Data are summarized as bar graphs or individual points; the mean 6 SEM is represented as a line. *P < .05, **P < .01, and ***P < .001, Student t test. NS, Not significant.
transplantation (BMT mice) in which either CD45.1 or CD45.2 donor bone marrow was transplanted into irradiated recipient CD45.2 mice and challenged them with Alternaria (as described in the Methods section in this article's Online Repository). In both the CD45.1 and CD45.2 BMT mice, more than 95% of all hematopoietic cells in the blood were of donor origin (Fig 3, D and E). Alternaria challenge significantly increased CD45.1 ILC2 numbers in the blood and lungs of the CD45.1 donor BMT mice but did not increase CD45.2 ILC2 numbers (Fig 3,  F and G, and see Fig E6 , A-C, in this article's Online Repository at www.jacionline.org). In addition, there was a significant increase in the total number of proliferating (Ki-67-expressing) CD45.1 ILC2s in the Alternaria-challenged CD45.1 BMT mice compared with the naive CD45.1 BMT mice (Fig 3,  H) . There were few Ki-67-expressing CD45.2 ILC2s in both the naive and Alternaria-challenged CD45.1 BMT lungs (see Fig E6, D) . These results suggest that ILC2s migrate from the bone marrow to the lungs.
In vivo blocking of b 2 integrins reduced ILC2 recruitment to the lung
Because of the high levels of b 2 integrins we noted to be expressed on both human and mouse ILC2s, we examined whether administering neutralizing antibodies to b 2 integrins would inhibit the accumulation of ILC2s in the lungs of Alternaria-challenged mice (Fig 4, A) . Alternaria-challenged mice treated with control antibody had significantly higher total numbers of ILC2s in the lungs compared with naive mice (Fig  4, B) . In contrast, Alternaria-challenged mice pretreated with an aCD18 b 2 integrin blocking antibody had significantly reduced absolute ILC2 numbers per lung compared with Alternaria-challenged mice (61.3% reduction of Alternaria-induced ILC2 increase in lung; Fig 4, B) .
In vivo blocking of b 2 integrins does not inhibit ILC2 proliferation or induce ILC2 apoptosis ILC2 levels of Ki-67 and Annexin V were determined to confirm that the effect of the aCD18 antibody on numbers of lung ILC2s after Alternaria challenge was due to inhibition of ILC2 migration rather than inhibition of ILC2 proliferation or induction of ILC2 apoptosis (Fig 4, C) . Alternaria challenge induced increased lung ILC2 proliferation, as previously described. 29 Administration of the aCD18 antibody to Alternaria-challenged mice did not inhibit lung ILC2 proliferation (Ki-67 1 ILC2s) or ILC2 apoptosis (Annexin V 1 ILC2s ; Fig 4, C) . Thus b 2 integrins are required for the accumulation of lung ILC2s from the blood without affecting proliferation or apoptosis.
Effect of in vivo blocking of b 2 integrins on ILC2 T H 2 cytokine expression
To determine whether pretreatment with the aCD18 antibody had an effect on activation of ILC2s, we assessed IL-5 and IL-13 production. Alternaria allergen challenge induced increased numbers of IL-5 1 ILC2s, IL-13 1 ILC2s, and ILC2s that were double positive for IL-5 and IL-13 (Fig 4, D) . The ILC2s in the lung after Alternaria allergen challenge include the ILC2-expressing T H 2 cytokines IL-5 and IL-13 (approximately 23% and 17% of total lung ILC2s, respectively), as well as a population of ILC2s not expressing T H 2 cytokines. Administration of the aCD18 antibody did not reduce cytokine-producing ILC2 numbers (Fig 4, D) , despite reducing the total number of ILC2s (Fig 4, B) , suggesting a reduction in the number of ILC2s that do not express T H 2 cytokines after administration of the aCD18 antibody (see Fig E7 in this article' s Online Repository at www. jacionline.org).
In vitro adhesion of ILC2s to ICAM-1 is dependent on b 2 integrins Sorted mouse lung ILC2s were plated on ICAM-1-coated plates and allowed to adhere for 90 minutes to determine direct interaction between ILC2s and ICAM-1 (as described in the Methods section in this article's Online Repository). There was a significant increase in the number of adherent ILC2s in ICAM-1-coated wells compared with control-coated wells (Fig 4, E) . Sorted ILC2s were preincubated in the presence or absence of the aCD18 antibody before plating on ICAM-1-coated plates to determine the role of b 2 in the adherence of ILC2s to ICAM-1. There was a significant reduction in the number of ICAM-1-adherent ILC2s in wells containing ILC2s preincubated with aCD18 compared with control ILC2s (Fig 4, E) . This demonstrates direct interaction between ILC2s and ICAM-1 in vitro, which is dependent on ILC2 expression of CD18.
In vivo blocking of the b 2 binding integrin a L inhibits ILC2 recruitment to the airways Both human and mouse ILC2s had high expression of a L , which is one of the a integrins that interacts with b 2 . Therefore we tested whether blocking the integrin a L b 2 (LFA-1) would also inhibit ILC2 recruitment to the airways. Alternaria-challenged mice pretreated with a blocking anti-a L integrin (aCD11a) antibody 30 had a significant reduction in lung ILC2 numbers compared with lung ILC2 numbers of Alternaria-challenged mice pretreated with the isotype control (Fig 4, F) .
In vivo blocking of either b 1 or a 4 integrins does not inhibit ILC2 recruitment to the airways Because ILC2s also express high levels of b 1 integrins, we investigated whether blocking this pathway would inhibit ILC2 numbers in the lung after Alternaria challenge. Alternaria-challenged mice pretreated with a blocking anti-b 1 integrin (aCD29) antibody 31 had no reduction in total lung ILC2 numbers (Fig 5, A) . Administration of the aCD29 antibody to Alternaria-challenged mice did not inhibit lung ILC2 proliferation (Fig 5, B) . Similarly, administration of the aCD29 antibody to Alternaria-challenged mice did not induce lung ILC2 apoptosis (Fig 5, C) .
Because the a 4 integrin (CD49d) can associate with either a b 1 integrin (a 4 b 1 ) or a b 7 integrin (a 4 b 7 ) , we also examined whether they expressed b 7 integrins. Human ILC2s from PBMCs, lymph nodes, and lungs were assessed for surface expression of integrin b 7 alone and for dual expression of CD49d and b 7 (Fig 5, D) . Human ILC2s, regardless of tissue source, showed low percentages of ILC2s expressing b 7 and even lower levels of ILC2s expressing both CD49d and b 7 (Fig 5, D) . In contrast to human ILC2s, mouse ILC2s expressed high levels of b 7 integrin in both naive (mean, 67.8%) and Alternaria-challenged (mean, 74.0%) mice (Fig 5, E) . Because of the high levels of a 4 b 1 and a 4 b 7 expression on mouse lung ILC2s, the role of blocking a 4 integrins in Alternaria-induced ILC2 recruitment was assessed.
Alternaria-challenged mice pretreated with a blocking anti-a 4 integrin (aCD49d) antibody 32 also had no reduction in total lung ILC2 numbers (Fig 5, F) . Administration of the aCD49d antibody to Alternaria-challenged mice did not inhibit lung ILC2 proliferation (Fig 5, G) . Similarly, administration of the aCD49d antibody to Alternaria-challenged mice did not induce lung ILC2 apoptosis (Fig 5, H) . These studies suggest that neither a 4 b 1 nor a 4 b 7 integrins play a significant role in ILC2 recruitment to the lung.
DISCUSSION
ILC2s expand in the lungs of mice during type 2 inflammation induced by Alternaria challenge. 13, 27 The increase in ILC2 numbers in the lung has previously been attributed to local proliferation alone 17 because studies have not demonstrated that ILC2s migrate from the circulation to the lung after allergen challenge. We report that both human and mouse ILC2s express high levels of b 1 and b 2 integrin adhesion receptors, which are known to be used by other circulating leukocytes to adhere to the endothelium and traffic to the lung. In addition, we show that after the 7-day Alternaria challenge, ILC2 numbers in the bone marrow decreased, whereas they increased in the circulation and lungs of mice, suggesting that ILC2s are released from the bone marrow to traffic to the lung after Alternaria challenge.
In addition, BMT studies demonstrated that ILC2s derived from bone marrow traffic to the lung after Alternaria challenge. In vivo blocking of b 2 integrins (CD18) before Alternaria allergen challenge in mice significantly diminished ILC2 numbers in the lungs. The effect of the aCD18 blocking antibody was specific to trafficking because aCD18 treatment did not affect Alternaria-induced ILC2 proliferation, apoptosis, or T H 2 cytokine expression. Moreover, in vitro, we demonstrated that ILC2s adhere to ICAM-1 and that the adherence was inhibited by blocking antibodies to the b 2 integrin. This was further confirmed by means of in vivo blocking of the a L integrin, a subunit of integrin a L b 2 (LFA-1), which showed a reduction in lung ILC2 numbers when aCD11a was administered.
Importantly, we also demonstrate that in vivo blocking of b 1 or a 4 integrins did not affect Alternaria-induced ILC2 levels in the airways. Therefore we demonstrate an additional novel mechanism by which Alternaria allergen challenge increases airway ILC2 levels by recruiting ILC2s from the bone marrow to the circulation through integrin-mediated trafficking that is dependent on b 2 integrins but not b 1 integrins.
We have previously demonstrated that human subjects with allergic rhinitis caused by cat allergen exposure when challenged with cat allergen in the laboratory experience a significant increase in numbers of peripheral blood ILC2s, which is not noted on a separate diluent nasal challenge visit. 9 In addition, ILC2 numbers in patients with grass pollen allergy increase in the blood during the grass pollen season. 33 These studies demonstrate that exposure to inhaled allergens in allergic subjects can significantly increase peripheral blood ILC2 numbers. At present, it is not known in human subjects whether the increase in peripheral blood ILC2 numbers after exposure to inhaled allergens is due to a signal to the bone marrow to release ILC2s from the bone marrow, which then traffic to tissue sites, such as the upper or lower airways, where they can express T H 2 cytokines and contribute to allergic inflammation. In contrast, studies in mice have provided evidence that ILC2s have tissue residency in the airways and do not recirculate. 16, 17 However, these studies have not examined whether expansion of ILC2 numbers in the lung after Alternaria challenge can be mediated by trafficking of ILC2s from the bone marrow to the lung.
Our study provides evidence that ILC2 numbers increase in the mouse lung after Alternaria allergen challenge through mechanisms that include b 2 integrin-mediated, but not b 1 integrinmediated, trafficking from the circulation to the lung, as well as because of local proliferation of ILC2s in response to local inflammatory mediators. These results are in agreement with a prior (Fig 5, A) , total Ki-67 1 ILC2s (Fig 5, B) , and live Annexin V 1 ILC2s (Fig 5, C) per mouse treated 6 anti-CD29 antibody (n > _ 6). D, Percentage of human ILC2s expressing integrin b 7 and both CD49d and b 7 from PBMCs (white columns; n 5 4), lung tissue (black columns; n 5 3), and lymph nodes (gray columns; n 5 4). E, Summary of the percentage of mouse lung ILC2s expressing CD49d and integrin b 7 from both naive and Alternaria-challenged mice (n 5 8). F-H, Total number of lung ILC2s (Fig 5, F) , total Ki-67 1 ILC2s (Fig 5, G), and live Annexin V 1 ILC2s (Fig 5, H) per mouse treated with or without anti-CD49d antibody (n > _ 5). The mean 6 SEM represented as a line. *P < .05, **P < .01, and ***P < .001, Student t test. NS, Not significant. study by our group showing that Alternaria challenge increases the percentage of Ki-67 proliferating ILC2s in the lungs. 15 When considered together, it is likely that one subset of ILC2s that are increased in the lung after Alternaria challenge are a result of migration from the blood, whereas a second subset of ILC2s are the pre-existing lung ILC2s that proliferate and increase ILC2 lung numbers independent of migration from the circulation. Because ILC2s express high levels of the b 2 integrin, which is known to mediate firm adhesion of other leukocytes to ICAM-1 expressed by endothelium, the reduction in lung ILC2 numbers we have noted in Alternaria-challenged mice treated with an aCD18 antibody can best be explained by reduced ILC2 b 2 integrin adhesion to ICAM-1 expressed by endothelium in the lung. Our in vitro studies demonstrated that ILC2s adhere to ICAM-1 in a b 2 integrin-dependent manner. Unfortunately, because ILC2s and endothelium both express ICAM-1, administration of an anti-ICAM-1 antibody to Alternaria-challenged mice would not only block ICAM-1 function on endothelium but also ICAM-1 function on ILC2s, making interpretation of this in vivo experiment problematic. One of the weaknesses of this study is the lack of the blocking of CD18 specifically on ILC2s, which would demonstrate direct CD18 expression on ILC2 involvement in ILC2 migration. In addition, our study demonstrates that the aCD18 antibody does not inhibit ILC2 numbers in the subset of ILC2s expressing T H 2 cytokines. This lack of inhibition of ILC2 T H 2 cytokine expression would be anticipated because there is currently no evidence that inhibition of b 2 integrins inhibits T H 2 cytokine responses.
Although we demonstrated that both human and mouse ILC2s expressed significant levels of b 1 integrins (a 4 b 1 or VLA-4), blocking b 1 integrin did not reduce the number of ILC2s in the lungs of Alternaria-challenged mice. Thus b 1 integrins are not as central as b 2 integrins in mediating the increase in the number of lung ILC2s after Alternaria challenge. In addition to b 1 and b 2 integrins, b 7 integrins (in particular a 4 b 7 ) can mediate adhesion to mucosal vascular addressin cell adhesion molecule 1 expressed by endothelium. In this study we found that b 7 integrin is expressed at low levels on human ILC2s isolated from PBMCs, lung tissue, and lung lymph nodes. Prior studies have also not detected significant expression of b 7 integrin on mouse lung ILC2s and human peripheral blood ILC2s. 34, 35 Thus b 7 integrins are unlikely to play a major role in human ILC2 adhesion. In contrast to human lung ILC2s, we did note high levels of b 7 integrin expression on mouse lung ILC2s. Prior studies have reported CD49d/b 7 integrin expression on the surfaces of mouse ILC precursors in the bone marrow 18 but minimal expression on mouse lung ILC2s. 34, 35 Despite the varying levels of mouse ILC2 CD49d/b 7 integrin expression reported in different studies, we demonstrated that inhibition of CD49d did not alter ILC2 numbers in the airways, and therefore CD49d/b 7 is unlikely to play a significant role in ILC2 migration to the lungs after Alternaria challenge. b 1 and b 2 integrins, which are expressed by ILC2s, bind to known counterreceptors, such as VCAM-1 and ICAM-1, expressed by vascular endothelium. Alternaria inhalation challenge is known to induce high levels of lung IL-33 within hours of challenge. 13 In addition, IL-33 has been shown to induce VCAM-1 and ICAM-1 expression by endothelial cells. 36 As this study demonstrated that blocking b 2 integrins (ie, the ICAM-1 counterreceptor pathway) reduced ILC2 numbers in the lung after Alternaria challenge and blocking the b 1 integrin pathway (ie, the VCAM-1 counterreceptor pathway) did not reduce lung ILC2 numbers, it suggests that either the VLA-4/VCAM pathway only mediates minor firm adhesion of ILC2s to the endothelium that can be bypassed by the b 2 integrin/ICAM-1 pathway or that VLA-4 expressed on ILC2 is in a low-affinity state, 37 which does not permit firm adhesion to the endothelium. We also demonstrated that mouse lung ILC2s did not express VCAM-1 but did express ICAM-1, which is in agreement with the results of another study. 34 In summary, this study makes the novel observation that expansion of ILC2s in the lung after Alternaria challenge is not only mediated by the well-described local lung proliferation of d ILC2s increase in number in the mouse lung not only through local proliferation but also through trafficking from the circulation into the lung using b 2 rather than b 1 or a 4 integrins.
METHODS
Human donor tissue collection
Viable human lungs, including lymph nodes (hilar and mediastinal), were obtained from organ donors postmortem by the Arkansas Regional Organ Recovery Agency and the National Disease Research Interchange and delivered to the laboratory. The acquisition of deceased donor tissue was reviewed by the University of Arkansas for Medical Sciences Institutional Review Board and determined not to be human subject research. Fresh normal peripheral blood leukapheresis cells (donors were nonsmokers aged 22-52 years) were purchased from AllCells (Alameda, Calif) and HemaCare (Van Nuys, Calif).
Isolation of single-cell suspensions from human tissue
Human lymph nodes were mechanically sheared with scissors and then passaged through a 70-mm filter to obtain a single-cell suspension. Human lung tissue was mechanically digested and then incubated at 378C until fully digested in a digestion buffer containing 200 U/mL collagenase (Liberase TL; Roche, Indianapolis, Ind), 20 U/mL DNase (Worthington Biochemical, Lakewood, NJ), 0.5% BSA, and 20 mmol/L HEPES in HBSS (Thermo Fisher Scientific, Waltham, Mass). Lung cells were then filtered, and red blood cells were lysed by using lysing buffer (BD Biosciences, San Jose, Calif). Peripheral blood leukapheresis cells were lysed for any remaining red blood cells by using lysing buffer (BD Biosciences). All tissues were then filtered and washed with PBS and assayed for ILC2s by using flow cytometry. 
Airway administration of Alternaria and in vivo blocking of integrins
Naive mice were challenged intranasally with 50 mg per dose in 50 mL of PBS of A alternata from Greer Laboratories (Lenoir, NC) after achievement of isoflurane (Vedco, St Joseph, Mo) anesthesia. Challenges were administrated 3 times (days 0, 3, and 6), and the mice were sacrificed 1 day after the final challenge (day 7), as previously described. E1 In experiments involving in vivo blocking of integrins, mice were administered intraperitoneally 100 mg/dose of an integrin-specific blocking antibody (either b 1 , b 2 , a 4 , or a L antibody; see Table E2 ) or its corresponding isotype 3 hours before each of the 3 intranasal administrations of Alternaria (days 0, 3, and 6). Blood cells were obtained through cardiac puncture directly into a syringe containing 100 mL of citrate concentrated solution (Sigma-Aldrich, St Louis, Mo). Blood was then treated with RBC lysis buffer (Sigma-Aldrich) to remove contaminating RBCs. Bronchoalveolar lavage fluid was collected by cannulating the trachea and lavaging the lungs initially with 0.8 mL of PBS followed by four 0.5-mL PBS lavages. Lungs were perfused with PBS before collection to reduce leukocyte infiltration from the blood. Whole lungs were processed into single-cell suspensions by using a lung dissociation kit and a tissue dissociator (both from Miltenyi Biotec, Auburn, Calif). Bone marrow cells were obtained by collecting both femurs and tibias from each mouse. Femurs or tibias were then perfused with 0.5% BSA in PBS, and the cell suspension obtained was incubated with RBC lysis buffer to remove RBCs. Spleens and lung lymph nodes were mechanically sheared with scissors and then passaged through a 70-mm filter to obtain a single-cell suspension. Spleen cells were then depleted of RBCs with RBC lysis buffer. Total cell counts and cell populations were quantified and assessed by using flow cytometry.
Bone marrow transplantation
CD45.2 recipient mice received sulfamethoxazole and trimethoprim antibiotic suspension (5 mL/250 mL of water; Hi-Tech Pharmacal, Amityville, NY) for 1 week before and 2 weeks after transplantation. Recipient mice were irradiated with a single dose of 10 Gy. Donor bone marrow cells were collected from naive CD45.1 or CD45.2 mice from both the tibias and femurs. Fifteen million bone marrow cells were injected into CD45.2 recipient mice by means of tail vein injection. BMT mice were allowed to rest for at least 6 weeks before intranasal challenge with Alternaria (7-day protocol). Peripheral blood chimerism was verified, and all BMT mice had greater than 95% hematopoietic cells originating from the donor.
Flow cytometry
A list of antibodies used is described in Tables E1 and E2 , and matching isotype controls were purchased from their respective companies. Singlecell suspensions were incubated with either human FcR blocking reagent (Miltenyi Biotec) or anti-mouse CD16/CD32 for 10 to 20 minutes on ice to block Fc receptors. Cells were stained with CD45.2, lineage markers (CD3, Gr-1, CD11b, CD45R, Ter-119, CD5, CD11c, FcεRI, NK1. with antibodies against the specific markers, as described in Tables E1 and E2 , to assess the expression of surface markers on both human and mouse ILC2s. Cells were permeabilized after surface staining by using the Foxp3 Staining Buffer Set and stained with anti-mouse Ki-67 (eBioscience, San Diego, Calif) to assess cellular proliferation. Apoptotic ILC2s were identified by staining with a fixable viability dye and Annexin V (eBioscience). Annexin V 1 stain was determined as a percentage of live ILC2 cells. Cells were incubated in the protein transport inhibitor GolgiPlug (BD Biosciences) to assess mouse ILC2 IL-5 and IL-13 production. After surface staining, cells were permeabilized with the BD intracellular staining kit and stained for anti-mouse IL-5 and IL-13 (eBioscience). In Figs 2, 4 , B, and 4, C, Ki-67 results were collected by using the Accuri C6 Flow Cytometer (BD Biosciences). All other sample data were collected with the Novocyte Flow Cytometer (Acea, San Diego, Calif), and data were analyzed with FlowJo software (Ashland, Ore).
ILC2 cell sorting and adhesion assay
Mice were challenged with Alternaria 3 times (days 0, 3, and 6) and killed on day 7. Whole lungs were perfused and processed into single-cell suspensions with a lung dissociation kit and a tissue dissociator (Miltenyi Biotech). Lung cells were stained with CD45.2, lineage markers, Thy1.2, and 49,6-diamidino-2-phenylindole dihydrochloride (DAPI; Invitrogen, Carlsbad, Calif). Lungs cells were then sorted for ILC2s on BD FACSAria II (BD Biosciences) and MoFlo XDP (Beckman Coulter, Indianapolis, Ind) cell sorters. Mouse lung ILC2s were identified as DAPI 2 CD45.2 1 Lin 2 Thy1.2 1 cells. Ninety-six-well plates were coated overnight at 48C with recombinant mouse ICAM-1 (25 mg/mL; BioLegend, San Diego, Calif) or with diluent as a control. All wells were blocked with 10% BSA in PBS for 30 minutes at room temperature. Wells were then washed twice with 0.5% BSA in PBS. Sorted ILC2s were preincubated with anti-mouse CD16/CD32 and then incubated with or without aCD18 blocking antibody (1 mg/mL) for 30 minutes at 48C. ILC2s were then washed and plated on the coated wells and allowed to adhere for 90 minutes at 48C, swirling the plate once midway to redistribute the unattached cells. The wells were then washed 5 times with cold PBS to remove nonadherent ILC2s. Adherent ILC2s were recovered by vigorously washing the wells with 0.5% BSA in PBS, and adherent cells were then counted by using flow cytometry.
Statistical analysis
DgMFI values were set to a minimum of 100. The mean difference in DgMFI between 2 populations (DDgMFI) was calculated as the mean difference between individual replicates. Student paired t tests were used to calculate statistical differences between DgMFI values of ILC2s and CD4 1 cells from the same donor or mouse. IL-5 and IL-13 cytokine expression data were log transformed to approximate normal distribution. All other comparisons were analyzed by using the Student t test. Error bars represent SEMs. Statistical analysis was performed with Prism software (GraphPad Software), and a 2-sided P value of .05 was considered statistically significant.
RESULTS
Human ILC2s express b 1 (CD29) integrins, b 2 (CD18) integrins, and L-selectin
Human peripheral blood, lung tissue, and intrathoracic lymph nodes were analyzed for ILC2 expression of adhesion molecules by using flow cytometry to determine whether human ILC2s express adhesion molecules commonly associated with migration of other leukocytes and specifically lymphocytes. Human ILC2s were gated as CD45 
CRTH2
1 lymphoid cells (Fig  1, A) . ILC2s were assessed for expression of the b 1 integrins (CD18 and CD11a) and b 2 integrins (CD29 and CD49d), as well as additional leukocyte-expressed adhesion molecules (ie, L-selectin [CD62L] and ICAM-1 [CD54]). VCAM-1 (CD106), which is known to be expressed by endothelium rather than leukocytes, was used as a likely negative control (Fig E1 shows representative adhesion molecule expression on human ILC2s).
Percentages of human peripheral blood, lung, and lymph node ILC2s expressing these surface markers are summarized in Fig  1, C-E. The majority of human ILC2s expressed both the a and b chains of the b 2 integrins (CD18 and CD11a) in blood (mean, 92.8% and 90.1%, respectively), lung (mean, 85.8% and 82.3%, respectively), and lymph nodes (mean, 75.7% and 73.5%, respectively; Fig 1, C-E) . The b 1 integrin (CD29) was also widely expressed on human ILC2s from blood (mean, 96.2%), lung (mean, 71.7%), and lymph nodes (mean, 49%; Fig 1, C-E) . In contrast, the a 4 integrin (CD49d), although commonly expressed on the surfaces of peripheral blood human ILC2s (mean, 72.3%), was expressed at reduced levels on human ILC2s from lung tissue (mean, 35.2%) and lymph nodes (mean, 16.3%; Figs 1, C-E, and E2). L-selectin (CD62L) was expressed on about half the human ILC2s from peripheral blood (mean, 49%; Fig 1, C-E) . However, it was only expressed on a minor percentage of human ILC2s from lung tissues (mean, 4.0%) and lymph nodes (mean, 2.4%; Figs 1, C-E, and E2). Human ILC2s also expressed ICAM-1 (CD54) at lower levels (mean, 44.1% in blood, 40.8% in lung, and 19.0% in lymph nodes) than CD18 and CD11a, whereas VCAM-1 (CD106), as expected, had minimal expression on human ILC2s (mean, 2.4% in blood, 1.8% in lung, and 1.4% in lymph nodes; Fig 1, C-E) . Thus human ILC2s highly express both integrin chains for LFA-1 (CD18 and CD11a) and moderately express both integrin chains for VLA-4 (CD29 and CD49d).
Comparison of human ILC2 and CD4 cell adhesion molecule expression
We compared the DgMFI of the human ILC2 population with the DgMFI of human CD4
1
CRTH2
1 lymphocytes from the same donors and tissues (Fig 1, F-H) . Overall, the relative expression of these b1 integrins, b2 integrins, and L-selectin adhesion molecules by human ILC2s was equivalent to that of human CD4
1
CRTH2
1 lymphocytes in the lung and lymph node (Fig  1, F-H) . In peripheral blood human ILC2s expressed slightly higher levels of a 4 integrins (CD49d; DDgMFI, 729), and lower levels of L-selectin (CD62L; DDgMFI, 10,123) compared with CD4 1
1 lymphocytes (Fig 1, F) . Thus, compared with human CD4 cells, human ILC2s express similar levels of b1 and b2 integrin adhesion molecules.
DISCUSSION
CD11 integrins
In leukocytes the b 2 integrin CD18 is known to heterodimerize with either CD11a, CD11b (integrin a M ), CD11c (integrin a X ), or CD11d (integrin a D ). Our study has not demonstrated which of these CD11 binding partners is likely to be a heterodimer with CD18 in promoting ILC2 recruitment to the lung. In this study we can exclude CD11b and CD11c as the CD18 binding partner because antibodies against CD11b and CD11c are used in the lineage cocktail in our and other studies to identify Lin 2 cells (ie, ILC2s) that do not express these markers. Whether ILC2 subsets express CD11b (a marker for mouse monocytes and macrophages) is still under debate, whereas studies of CD11c (a dendritic cell marker) have demonstrated low or dull expression on ILC2s.
E2 Therefore CD11c and CD11b are unlikely the predominant a integrin counterpart of CD18 involved in ILC2 adhesion. CD11d is also unlikely because CD11d/CD18 has been shown primarily in mouse spleen and bone marrow and at low levels on blood leukocytes. E3 Therefore although CD11d is still a possible candidate for ILC2 migration to the lung, it is very unlikely. We have demonstrated very high levels of expression of CD11a on both human and mouse ILC2s, as well as a reduction of lung ILC2 numbers in the airways after Alternaria challenge through in vivo blocking of CD11a. Together, this suggests that the primary integrin involved in ILC2 migration to the lungs after Alternaria challenge is CD11a/CD18 (LFA-1).
L-selectin
Although our study focused on the role of ILC2-expressed integrins in mediating ILC2 trafficking to the lung, we also examined whether L-selectin was expressed by human and mouse ILC2s in the peripheral circulation and lung because prior studies have demonstrated in the mouse that CD62L is present on the surface of precursor ILC2s and immature ILC2s in the bone marrow but not on mouse lung ILC2s.
E1,E4 L-selectin expression on leukocytes mediates the initial tethering of circulating leukocytes to inflamed endothelium. CD62L is present on naive and central memory T cells because once the T cells migrate to the tissues and become activated T cells, CD62L is shed and no longer expressed. E5 As L-selectin is shed, lower tissue levels of expression are expected, and the reduced tissue expression of L-selectin on ILC2s could be attributed to its shedding during leukocyte trafficking. We confirmed that in the mouse, ILC2s in lung tissue did not express CD62L. Because a subset of mouse lung CD4 1 Thy1.2 1 cells expressed CD62L, this suggests that lung processing did not cause CD62L shedding. In addition, because studies of CD62L have not been performed in human lungs and lymph nodes, we performed studies comparing human CD62L expression by peripheral blood ILC2s with these tissue ILC2s. These studies demonstrate that in human subjects, as in mice, CD62L is expressed by peripheral blood ILC2s. In contrast, CD62L is expressed at low levels on human ILC2s in the lungs and lung lymph nodes, suggesting it has been shed on migration into the lungs. (Fig E5, A) and spleens ( Fig E5, B) from naive (white columns; n > _ 8), 4-day Alternaria challenged (gray columns; n > _ 4), and 7-day Alternaria-challenged (black columns; n > _ 4) mice. C-G, Total CD45 1 leukocytes from bone marrow (Fig E5, C) , blood (Fig E5, D) , whole lungs ( Fig E5, E) , lung lymph nodes (Fig E5, F) , and spleens ( Fig E5, G) from naive (white bars) and 4-day (gray bars) and 7-day Alternaria-challenged mice (black bars). Data are summarized as bar graphs representing means 6 SEMs. *P < .05, **P < .01, and ***P < .001, Student t test. NS, Not significant. (Fig E6, A) or Alternariachallenged (Fig E6, B) CD45.1 BMT mouse lung ILC2s and naive CD45.2 BMT mouse lung ILC2s (Fig E6, C) . 
